论文部分内容阅读
《新英格兰医学杂志》网站最近刊出的研究报告说,一种被广泛用于治疗糖尿病的药物罗格列酮(商品名:文迪雅)可能大幅增加心脏病风险,导致死亡率增加。罗格列酮在临床上的使用非常广泛,年销售额大约几十亿美金。造成生产该药的英国葛兰素史克制药公司(Glaxo-SmithK line)的股价大跌逾8%。就在《新英格兰医学杂志》发布研究结果不久,GSK公司在其官方网站发布公告,声明“极其不认同”该研究结果,同时《柳叶刀》杂志也发表社论,对《新英格兰医学杂志》公布的数据表示质疑,一些统计学专业人士也对该研究的设计和统计方法提出了质疑。不知道各位对此事件有何高见?
A recent study published in the New England Journal of Medicine said rosiglitazone, a widely used drug for the treatment of diabetes (brand name: Avandia), could dramatically increase the risk of heart disease and lead to increased mortality. Rosiglitazone in the clinical use of a very wide range of annual sales of about billions of dollars. Shares of Glaxo-SmithK line, the maker of the drug, have plunged more than 8%. Shortly after the study was published in the New England Journal of Medicine, GSK issued a public announcement on its official website stating “extremely disagree” with the findings and published an editorial in The Lancet magazine, announcing that “New England Journal of Medicine” Published data questioned some of the statistics professionals also questioned the design and statistical methods of the study. I do not know what you think about this incident?